Added to basket
Unapplied Changes
CROMA-PHARMA®, a global leader in minimally-invasive aesthetic medicine, is excited to announce that its range of injectable polynucleotides “PhilArt” is rebranding to better reflect the products’ exceptional attributes and to position them for global market expansion.
PolyPhil™ succeeds the well-established PhilArt range, offering a unique, effective portfolio of injectable polynucleotides known for their safety, efficacy, and cutting-edge technology.This change will enhance the products’ recognition across international markets, reinforcing Croma’s commitment to providing pioneering and effective treatments.
With the on-going demand for our Polynucleotide portfolio, this name change will better encompass what the product does and will broaden reach in all markets, aiding to global brand awareness. The quality and efficacy of the product remain unchanged and Croma UK will dedicate investment and support for this rebrand. Vikki Baker, Head of Marketing UK IRE NL
Key benefits of PolyPhil™:
◆ Safety and Tolerance: Biocompatible with a minimal risk of adverse effects 1
◆ Biorevitalisation of the Skin: Enhances skin structure, elasticity, and density
◆ Collagen stimulation: Activates natural mechanisms for collagen synthesis and regeneration
◆ Versatile Applications: Effective for the face, neck, décolletage, hands, and delicate eye areas
◆ High Patient Satisfaction: 91% clinical improvement in reducing fine lines and improving skin quality 2
Unlock innovation with PolyPhilTM
PolyPhil™ has proven efficacy supported by extensive clinical data.1
It utilises the polynucleotides – high purification technology (PN-HPT™), derived from water sources
in a controlled environment ensuring safety and quality through a unique technology in a European-based production facility.
More than just a skin booster – A versatile treatment tool
With the Skin Enhancement Technique (SET), PolyPhil™ complements other aesthetic treatments such as laser therapies, microneedling, and chemical peels. This combination enables natural restoration for optimal skin conditions.1
References:
1. Cavallini et al. Consensus report on the use of PN-HPT™ (polynucleotides highly purified technology) in aesthetic medicine J Cosmet Dermatol. 2020;00:1–7.
2. Cavallini and Papagni, Long chain polynucleotides gel and skin biorevitalization; Journal of Plastic Dermatology 2007; 3,
Results
 |
Female, 26 years old, Problem: acne scars | Treatment with PolyPhil | Frequency: 3 sessions every 2-3 weeks | Targeted area for treatment: cheeks and chin | Amount of product used/side: 1.0 ml | Injection technique: Microdroplet/fanning | Injection depth (layer): Intradermal | Amount/Injection: 1.0-0.3 ml | Result after 8 weeks. Images courtesy of Dr. Alexandra Ogilvie |
 |
Female, 51 years old, Problem: scar | Treatment with Polyphil, PolyPhil eye | Frequency: 3 sessions every 4 weeks | Targeted area for treatment: chin and upper lip (scars) full face, periocular | Amount of product used/side: 1.0 ml |Injection technique: Microdroplet/fanning | Injection depth (layer): Intradermal | Amount/Injection: 1.0-0.3 mlImage. Images courtesy of Dr. Alexandra Ogilvie |
Croma-Pharma® is a global player in the minimally invasive aesthetics market and a leading European manufacturer of premium quality hyaluronic acid syringes. The company offers a comprehensive and innovative aesthetics portfolio including botulinum toxin, fillers, lifting threads, Polynucleotides, PRP and biostimulators complemented by its own skincare brand. Founded in 1976 by the pharmacist couple Prinz, Croma-Pharma® GmbH is a family company headquartered in Austria where it also operates itsmanufacturing plant. With 550 employees, 13 subsidiaries in Europe and Brazil, two joint ventures and 60 exclusive export partners, it distributes its products in 80 markets globally, including the US/Canada, China and Australia/New Zealand. It also operates as a contract manufacturer in orthopaedics and ophthalmology. For more information please visit cromapharma.com.
For more information please contact us: info.uk@cromapharma.com
